(44) retrospectively studied the efficacy of chemotherapy alone or ICI-combo in 135 patients with ES-SCLC, who were stratified into “inflamed tumor” and “non-inflamed tumor” groups based on both PD-L1 (≥1%), positive score (CPS), and CD8+ tumor-infiltrating lymphocyte (TIL) density (≥85/mm2) and found that MYC (P = 0.02) and SOX11 (P < 0.001) were the two most upregulated genes in “non-inflamed tumors” compared to those in “inflamed tumors,” suggesting that MYC has weak immunoreactivity in SCLC. The gene discussed is SOX11; the disease is neoplasm.